home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

17.24 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

21 22 Next >

Why Intellia Therapeutics Stock Is Surging Tuesday ↗

November 14, 2023

Intellia Therapeutics Inc (NYSE: NTLA) shares are trading higher Tuesday after the company announced it received European Union orphan d

Via Benzinga

Cathie Wood Continues On Roku Shares Selling Spree After Company's Q3 Revenue Jump — Ark Sells $21.1M Of Stock ↗

November 13, 2023

Via Benzinga

Analyst Ratings for Intellia Therapeutics ↗

November 10, 2023

Via Benzinga

3 Biotech Stocks That Are Betting on the Future of Gene Editing ↗

November 09, 2023

These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.

Via InvestorPlace

Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners ↗

November 06, 2023

Roku vaulted 50% to become Ark Innovation's top holding.

Via Investor's Business Daily

2 Brilliant Growth Stocks to Buy and Hold Forever ↗

October 12, 2023

These two growth stocks could be genuine wealth escalators.

Via The Motley Fool

Down 45%, Is Intellia a Buy? ↗

October 10, 2023

Intellia's operating in the high-growth field of gene editing.

Via The Motley Fool

1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years ↗

November 02, 2023

Biotech may be in a slump, but this innovator holds enormous promise as a potential wealth escalator.

Via The Motley Fool

Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy? ↗

October 28, 2023

There's more to being a good investment than doing groundbreaking science.

Via The Motley Fool

3 Stocks Cathie Wood Is Buying That Should Be on Your List Too ↗

October 23, 2023

The three companies are positioned to benefit from red-hot trends.

Via The Motley Fool

Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time ↗

October 21, 2023

Wood is going all in on gene editing.

Via The Motley Fool

Cathie Wood's Ark Offloads $6.3M In Tesla Shares Amid EV Maker's Q3 Earnings Disappointment ↗

October 18, 2023

Via Benzinga

3 Gene Editing Stocks to Generate Super-Charged Gains ↗

October 18, 2023

As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.

Via InvestorPlace

Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing ↗

October 18, 2023

The company can begin a pivotal study of its treatment for cardiomyopathy.

Via Investor's Business Daily

2 Healthcare Stocks Near 52-Week Highs Still Worth Buying ↗

October 16, 2023

These two large-cap biopharma companies could have more room to run.

Via The Motley Fool

2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years ↗

October 14, 2023

These two gene-editing stocks could be diamonds in the rough.

Via The Motley Fool

Cathie Wood's Ark Invest Sells $9.8M Worth Of Tesla Shares — Second Day Of Selling EV Giant In A Row ↗

October 11, 2023

Via Benzinga

Cathie Wood's Ark Invest Keeps On Cutting Tesla Holdings, Sells More Than $8M Worth Of EV Maker's Shares ↗

October 10, 2023

Via Benzinga

This Cathie Wood Stock Is Poised to Double, Says Wall Street ↗

October 10, 2023

Almost anything is possible in the volatile biotech industry.

Via The Motley Fool

Intellia Therapeutics Could Rise 167%, Per Wall Street, But Is It a Buy? ↗

October 03, 2023

Don't bet the farm on the analysts being right -- but they might be.

Via The Motley Fool

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

October 03, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Are Gene Therapy Stocks The Market's Next Big Winners?

September 25, 2023

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

Via MarketBeat

Topics Artificial Intelligence

Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals ↗

September 23, 2023

Rocket could launch its medicines sooner, but Intellia is aiming for larger markets.

Via The Motley Fool

1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know ↗

September 19, 2023

Good medicines aren't always good business.

Via The Motley Fool

2 Top Trends to Invest $500 In Right Now ↗

September 18, 2023

Early investors in these trends may reap the rewards over time.

Via The Motley Fool

Cathie Wood Is Buying These 2 Biotech Stocks Hand Over Fist, and Wall Street Thinks They Could Double ↗

September 10, 2023

These businesses could be on the verge of takeoff.

Via The Motley Fool

Cathie Wood Is Buying This Stock Hand Over Fist. Should You? ↗

September 06, 2023

Intellia has declined in the double digits over the past year.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

September 01, 2023

The widely followed growth investor went stock shopping on the final trading day in August.

Via The Motley Fool

Cathie Wood's Ark Invest Increases Palantir Exposure By $10.08M Amid Market Volatility, Offloads Shopify Stock ↗

August 31, 2023

Via Benzinga

The 3 Most Promising Biotech Stocks to Own Now ↗

August 31, 2023

These top biotech stock picks with high and leading growth potential are must-owns for investors looking for high upside potential.

Via InvestorPlace

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com